397 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Rank Status Study
21 Recruiting Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dabrafenib;   Biological: ipilimumab;   Drug: trametinib;   Other: laboratory biomarker analysis
22 Not yet recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
23 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
24 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
25 Recruiting Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Conditions: Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma
Interventions: Biological: sargramostim;   Procedure: sentinel lymph node biopsy;   Other: laboratory biomarker analysis;   Other: hypertonic saline
26 Recruiting Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ziv-aflibercept;   Biological: aldesleukin;   Other: laboratory biomarker analysis
27 Recruiting Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Biological: recombinant interleukin-15;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
29 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Biological: ipilimumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
30 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab
31 Recruiting Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIc Melanoma;   Stage IV Melanoma
Interventions: Other: laboratory biomarker identification and analysis;   Procedure: biopsy;   Other: immunohistochemistry/tissue microarrays;   Genetic: TdT-mediated dUTP nick end labeling assay;   Other: mass spectrometry;   Radiation: positron emission tomography (PET)/computed tomography (CT)
32 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: bevacizumab;   Biological: ipilimumab
33 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
34 Recruiting A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Conditions: V600-mutated BRAF Unresectable Melanoma;   V600-mutated BRAF Metastatic Melanoma;   Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Interventions: Drug: PLX3397;   Drug: vemurafenib
35 Recruiting Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab
36 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
37 Recruiting Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib
Conditions: Metastatic Melanoma;   Melanoma;   BRAF-mutated Metastatic Melanoma;   V600EBRAF-mutated Metastatic Melanoma
Intervention: Drug: Vemurafenib, Decitabine
38 Recruiting Adoptive T Cell Therapy for Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Tumor Infiltrating Lymphocytes
39 Recruiting Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
Conditions: Malignant Melanoma of Skin Stage III;   Metastatic Melanoma
Intervention: Drug: Rituxan
40 Not yet recruiting Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma
Interventions: Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC);   Biological: Autologous PBMCs in GM-CSF (MC)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years